GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acasti Pharma Inc (TSXV:ACST) » Definitions » Cash Flow from Financing

Acasti Pharma (TSXV:ACST) Cash Flow from Financing : C$9.96 Mil (TTM As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Acasti Pharma Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Dec. 2023, Acasti Pharma paid C$0.00 Mil more to buy back shares than it received from issuing new shares. It received C$0.00 Mil from issuing more debt. It paid C$0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received C$0.00 Mil from paying cash dividends to shareholders. It received C$0.00 Mil on other financial activities. In all, Acasti Pharma spent C$0.00 Mil on financial activities for the three months ended in Dec. 2023.


Acasti Pharma Cash Flow from Financing Historical Data

The historical data trend for Acasti Pharma's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acasti Pharma Cash Flow from Financing Chart

Acasti Pharma Annual Data
Trend Feb13 Feb14 Feb15 Feb16 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 61.09 18.40 74.77 - 0.42

Acasti Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 9.96 -

Acasti Pharma Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Acasti Pharma's Cash from Financing for the fiscal year that ended in Mar. 2023 is calculated as:

Acasti Pharma's Cash from Financing for the quarter that ended in Dec. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$9.96 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Acasti Pharma  (TSXV:ACST) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Acasti Pharma's issuance of stock for the three months ended in Dec. 2023 was C$0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Acasti Pharma's repurchase of stock for the three months ended in Dec. 2023 was C$0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Acasti Pharma's net issuance of debt for the three months ended in Dec. 2023 was C$0.00 Mil. Acasti Pharma received C$0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Acasti Pharma's net issuance of preferred for the three months ended in Dec. 2023 was C$0.00 Mil. Acasti Pharma paid C$0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Acasti Pharma's cash flow for dividends for the three months ended in Dec. 2023 was C$0.00 Mil. Acasti Pharma received C$0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Acasti Pharma's other financing for the three months ended in Dec. 2023 was C$0.00 Mil. Acasti Pharma received C$0.00 Mil on other financial activities.


Acasti Pharma Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Acasti Pharma's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Acasti Pharma (TSXV:ACST) Business Description

Traded in Other Exchanges
Address
3009 Boulevard de la Concorde East, Suite 102, Laval, QC, CAN, H7E 2B5
Acasti Pharma Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery all of which could help to increase treatment compliance and improve patient outcomes.
Executives
Donald John Olds Director

Acasti Pharma (TSXV:ACST) Headlines

From GuruFocus

Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31

By Stock market mentor Stock market mentor 01-24-2023

Acasti Pharma to Present at Sidoti Virtual Investor Conference on January 18

By Stock market mentor Stock market mentor 01-13-2023